Authors
You Can Build AI In-House. But Should You?
Sr. Principal, Patient Analytics and AI, Team Lead, Global Commercial Solutions, IQVIA
VP and general manager, global medical affairs and HCP engagement, IQVIA
Senior Vice President, Commercial, Stealth Biotech PBC
Vice president and general manager, product management, at IQVIA, where he leads the development of the Commercial Analytics, Agentic, & GenAI Solutions business globally. With over 20 years of experience in technology, data, and analytics, Nasir has held various leadership roles, including senior director and general manager, senior director of machine learning, and director offering lead.
Sierra Benbrook is a Senior Director with Alvarez & Marsal's Life Sciences Group in Dallas, Texas. She works with Pharma, distributors, PBMs, and pharmacies to design the next generation of business models and customer strategies at a time of rapid disruption and convergence across healthcare.
Her knowledge base spans corporate finance, M&A, growth-led transformations, go-to-market strategies, and operating model design, with a specialization in patient services, market access, specialty pharmacy, and channel and trade strategies.
James "Jim" Cleffi is a Managing Director with Alvarez & Marsal's Life Sciences Industry Group in Philadelphia. He specializes in transformational strategies focused on business growth, commercial models, M&A and customer strategies, working across the healthcare ecosystem with a focus on growth and stakeholder value.
Mr. Cleffi brings more than 20 years of experience driving high-value transformations oriented towards business growth, operational improvement and distinctive customer capabilities across the globe, advising leading and emerging life sciences companies with an entrepreneurial and deep customer perspective.
Author of Executive Presence: Step Into Your Power, Convey Confidence, & Lead With Conviction. He has coached more than 2,500 leaders, including pharma and biotech executives.
Aisling O'Loughlin, Ph.D., is a Principal at IQVIA working at the intersection of AI, innovation and strategy consulting. She leads AI and advanced analytics engagements, applying algorithms along the patient journey and across the asset lifecycle to draw meaningful value from data, and pairs big data, models and bespoke technology with human expertise to support better-informed, faster decisions. She holds a doctorate in gene therapy and neuroscience and an MSc in neuroscience from the University of Oxford, and a BSc in neuroscience and pharmacology from University College Dublin.
Strategic Advisor, Rocket Pharmaceuticals
Megan Shea is a Director with Alvarez & Marsal's Life Sciences Group in Boston, Massachusetts. She is focused on advising Life Sciences companies including BioPharma, Pharmacy, MedTech, Diagnostics, and Wholesalers and Distributors, with experience advising private equity firms and life sciences corporations on M&A opportunities and corporate growth strategy. Her knowledge base spans the biopharma value chain including R&D, manufacturing, and commercialization, as well as the medical device and diagnostics industries.
Troy joined Rapport in 2023 with more than two decades of financial leadership experience in the biotech and pharmaceuticals sectors. Over the course of his career, Troy has raised more than $4 billion in capital for life science companies, leading to 8 FDA approved products. Most recently, he was Chief Financial Officer at Karuna Therapeutics, prior to its sale to BMS, where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings. Prior to Karuna, Troy served as Chief Financial Officer at two other companies, Juventas Therapeutics and scPharmaceuticals. He has a long track record of experience in the sector, having started out at Eli Lilly and then moving on to roles of increasing responsibility at companies including Esperion Therapeutics and the former Insys Therapeutics. Previously, Troy served on the board of CinCor Pharma, Inc., where he advised on the company’s sale to AstraZeneca in early 2023, and currently serves on the boards of Abivax (ABVX), Contineum Therapeutics (CNTM) and Harmony Biosciences (HRMY). Troy is also an advisor to Sofinnova Investments and Patients Capital Management.
Senior Manager, Simon-Kucher, Warsaw
Health Services Sector Leader, PwC
Executive partner, leadership advisory, WittKieffer